Assess NK Cell Function and Phenotype
Natural Killer (NK) cells perform immunological surveillance as one of the body’s first responders to infections and cancer. Understanding NK biology and activity is critical to fully exploit their immune response potential. Use Incucyte® live-cell imaging and analysis and iQue® 3 High-Throughput 선별 (HTS) by Cytometry for activities such as immunophenotyping, assessment of functional activity, cell viability, immunophenotyping, and profiling of cytolytic effector proteins, cytokines, and chemokines.
Request More Information
Learn more about Immunology
® Blended phase and fluorescent images of SKOV-3 Incucyte® NucLight Red spheroids in the presence immune cells, either untreated or in the presence of anti-CD3 (10 ng/ml) and IL-2 (10 ng/ml) or Herceptin (0.08 – 50 ug/mL). 세포독성 was quantified based on the red fluorescent intensity. Data demonstrates destruction of tumor spheroids by the activated T-cell population and a Herceptin-induced cell 세포독성.
자연살해세포 mediated-antibody-dependent cellular 세포독성 induces concentration dependent target 세포사, granzyme production.
Encoded Raji tumor cells (20K/well) were co-cultured with PBMCs (200K/well) from two separate donors. PBMCs were incubated with one of three anti-CD20 antibodies: Ab-1 (IgG1), Ab-2 (IgG1) or a negative control Ab-3 (IgA2). Concentration range was between 10ug/mL – 0.128 ng/mL.
At 4h, 10 µL samples were analyzed to assess tumor cell killing using the Human NK Cell Killing Kit and the iQue® 3, Granzyme A was also measured using an iQue® Human NK Cell Companion Kit. (A,B) Target cell killing by two donors show differential response to the antibodies. (C,D) Granzyme A production was both concentration and donor dependent. (E,F) Detection of CD16 on NK cells decreased with increasing concentration of anti-CD20 antibody. This could be due to CD16 shedding or competition of CD20 antibody.
Encoded K562 tumor cells (20K/well) were co-cultured with enriched (음성 선별) human NK cells that had been incubated for 16-18 h in either media alone (Non-activated NK cells) or media containing 200 U/mL IL-2 & 100 ng/mL IL-15 (Activated NK cells) at an Effector:Target ratio of 1:1 or 5:1. At 4 h and 24 h, 10 µL samples were analyzed to assess tumor cell killing using the iQue® Human NK Cell Killing Kit and the iQue® 3. (A) Histogram depicting target cell viability following co-culture with non-activated or 사이토카인 activated NK cells for 4 h. (B,C) Summary of percent target 세포사 following co-culture of tumor cells with non-activated or 사이토카인 activated NK cells for (B) 4 h or (C) 24 h.
Encoded K562 tumor cells (20K/well) were co-cultured with enriched (음성 선별) human NK cells that had been incubated for 16-18 h in either media alone (Non-activated NK cells) or media containing 200 U/mL IL-2 & 100 ng/mL IL-15 (Activated NK cells) at an Effector:Target ratio of 5:1. Following 24 h of co-culture, 10 µL samples were removed and analyzed using the iQue® Human NK Cell Killing Kit and the iQue® HTS Platform. (A) Expression of activation markers, CD69 and CD25. (B) Production of IFNg and Granzyme B secretion. (C) Additional cytokines were assessed in parallel by combining iQue® Human NK Cell Companion Kits with the iQue® Human NK Cell Killing Kit. NK = Natural Killer cells. T = Target K562 tumor cells.
Activation with IL-2 and IL-15 caused increased activation 표지자 expression and secretion of multiple effector proteins, such as Granzyme B and CCL5 (RANTES). These effects were further enhanced when NK cells were cultured with target cells.
For further reading:1. Tarazona R et al. Cancer Immunol Immunother. 2020 May;69(5):879-899. doi: 10.1007/s00262-020-02532-9. Epub 2020 Mar 42. Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: J Clin Invest. 2019 Sep 3;129(9):3499-3510. doi: 10.1172/JCI1293383. Waggoner SN et al. Curr Opin Virol. 2016 Feb;16:15-23. doi: 10.1016/j.coviro.2015.10.008. Epub 2015 Nov 164. Yao Z, Zheng Z, Wu K1, Junhua Z.Aging (Albany NY). 2020 May 2;12. doi: 10.18632/aging.103101
NK in Tumor Cell Suppression and Resistance
Sarhan D, et al. Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21
Kamiya T, Seow SV, Wong D, Robinson M, Campana D. J Clin Invest. 2019 Mar 12;129(5):2094-2106. doi: 10.1172/JCI123955. Print 2019 May 1
NK CAR
Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5. doi: 10.1016/j.stem.2018.06.002. Epub 2018 Jun 28
High Throughput ADCC Assay Development
Camacho-Sandoval R, et al. Biotechnol Rep (Amst). 2020 Apr 19;26:e00456. doi: 10.1016/j.btre.2020.e00456. eCollection 2020 Jun
Boudreau CM, Yu WH, Suscovich TJ, Talbot HK, Edwards KM, Alter G. J Clin Invest. 2020 Feb 3;130(2):662-672. doi: 10.1172/JCI129520
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.